vestarВестник аритмологииJournal of Arrhythmology1561-86412658-7327НАО «Инкарт»10.35336/VA-2021-3-e1-e4vestar-998Research ArticleПИСЬМО В НОМЕРЛечение фибрилляции предсердий в России: работа над ошибкамиAtrial fibrillation treatment in Russia: work on bugshttps://orcid.org/0000-0003-1510-9204КанорскийС. Г.KanorskiiS. G.

Краснодар, ул. имени Митрофана Седина, 4

Krasnodar, 4 Mitrofana Sedina str.

kanorskysg@mail.ruФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РоссииРоссияKuban State Medical UniversityRussian Federation202126102021283e1-e4Copyright © Канорский С.Г., 20212021Канорский С.Г.Kanorskii S.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestar.elpub.ru/jour/article/view/998

В статье рассматриваются результаты опроса врачей Российской Федерации с целью изучения подходов к лечению фибрилляции предсердий в реальной клинической практике и сопоставления полученных результатов с действующими клиническими рекомендациями. Представлены некоторые новые данные, способные изменить рекомендации в будущем; обсуждаются возможные причины врачебных ошибок и пути их исправления.

The article discusses the results of a survey of doctors in the Russian Federation with the aim of studying approaches to the treatment of atrial fibrillation in real clinical practice and comparing the results obtained with the current clinical guidelines. Some new data are presented that could change the recommendations in the future; possible causes of medical errors and ways to correct them are discussed.

фибрилляция предсердийантиаритмические препаратыпероральные антикоагулянтыкатетерная аблацияatrial fibrillationantiarrhythmic drugsoral anticoagulantscatheter ablationReferencesШубик ЮВ, Медведев ММ, Михайлов ЕН, Гасымова НЗ, Гиляров МЮ. Лечение фибрилляции предсердий в России: реальная клиническая практика и рекомендации. Вестник аритмологии. 2021;28(2): 55-63. https://doi.org/10.35336/VA-2021-2-55-63.Shubik YuV, Medvedev MM, Mikhaylov EN, Gasimova NZ, Gilyarov MYu. Management of atrial fibrillation in Russia: real clinical practice and current clinical guidelines. Journal of Arrhythmology. 2021;28(2): 55-63 (In Russ.). https://doi.org/10.35336/VA-2021-2-55-63.Аракелян МГ, Бокерия ЛА, Васильева ЕЮ, и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7): 4594. https://doi. org/10.15829/1560-4071-2021-4594.Arakelyan MG., Bockeria LA., Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7): 4594. (In Russ.). https://doi. org/10.15829/1560-4071-2021-4594.Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5): 373-498. https://doi. org/10.1093/eurheartj/ehaa612.Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5): 373-498. https://doi. org/10.1093/eurheartj/ehaa612.Kirchhof P, Camm AJ, Goette A, et al. EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14): 1305-1316. https://doi.org/10.1056/NEJMoa2019422.Kirchhof P, Camm AJ, Goette A, et al. EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14): 1305-1316. https://doi.org/10.1056/NEJMoa2019422.Kim D, Yang PS, You SC, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021;373: n991. https://doi.org/10.1136/bmj.n991.Kim D, Yang PS, You SC, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021;373: n991. https://doi.org/10.1136/bmj.n991.Rillig A, Magnussen C, Ozga AK, et al. Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure. Circulation. 2021 Jul 30. https://doi.org/ 10.1161/CIRCULATIONAHA.121.056323. Online ahead of print.Rillig A, Magnussen C, Ozga AK, et al. Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure. Circulation. 2021 Jul 30. https://doi.org/ 10.1161/CIRCULATIONAHA.121.056323. Online ahead of print.Pantlin PG, Bober RM, Bernard ML, et al. Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease. J Cardiovasc Electrophysiol. 2020;31(3): 607- 611. https://doi.org/10.1111/jce.14335.Pantlin PG, Bober RM, Bernard ML, et al. Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease. J Cardiovasc Electrophysiol. 2020;31(3): 607- 611. https://doi.org/10.1111/jce.14335.Миронов НЮ, Юричева ЮА, Влодзяновский ВВ, и др. Опыт клинического применения отечественного антиаритмического препарата III класса для медикаментозной кардиоверсии фибрилляции и трепетания предсердий: результаты многоцентрового исследования. Часть 1: методология исследования и оценка эффективности. Рациональная Фармакотерапия в Кардиологии 2021;17(2): 193-199. https://doi. org/10.20996/1819-6446-2021-03-05.Mironov NY, Yuricheva YA, Vlodzyanovskiy VV., et al. Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology 2021;17(2): 193-199. (In Russ.). https://doi. org/10.20996/1819-6446-2021-03-05.Duytschaever M, Demolder A, Phlips T, et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018;39(16):1429-1437. https://doi.org/10.1093/eurheartj/ehx666.Duytschaever M, Demolder A, Phlips T, et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018;39(16):1429-1437. https://doi.org/10.1093/eurheartj/ehx666.January CT, Wann LS, Calkins H, et al. 2019 AHA/ ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2): e125-e151. https://doi.org/10.1161/ CIR.0000000000000665.January CT, Wann LS, Calkins H, et al. 2019 AHA/ ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2): e125-e151. https://doi.org/10.1161/ CIR.0000000000000665.

The authors declare that there are no conflicts of interest present.